Agenzia Italiana del Farmaco
COVID-19 Vaccine AstraZeneca: Risk of thrombocytopenia and coagulation disorders - COVID-19 Vaccine AstraZeneca: Risk of thrombocytopenia and coagulation disorders
COVID-19 Vaccine AstraZeneca: Risk of thrombocytopenia and coagulation disorders
COVID-19 Vaccine AstraZeneca: Risk of thrombocytopenia and coagulation disorders.
Summary:
- COVID-19 Vaccine AstraZeneca: benefits outweigh the risks despite possible link to very rare blood clots with low blood platelets.
- A combination of thrombosis and thrombocytopenia, in some cases accompanied by bleeding, has been observed very rarely following vaccination with COVID-19 Vaccine AstraZeneca.
- Healthcare professionals should be alert to the signs and symptoms of thromboembolism and or thrombocytopenia.
- Those vaccinated should be instructed to seek immediate medical attention if they develop symptoms such as shortness of breath, chest pain, leg swelling, persistent abdominal pain following vaccination. Additionally, anyone with neurological symptoms including severe or persistent headaches and blurred vision after vaccination, or who experiences skin bruising (petechia) beyond the site of vaccination after a few days, should seek prompt medical attention.
Published on: 24 March 2021